Next Generation Stroke Prevention: Factor XI Inhibition in Atrial Fibrillation - Powered by BMS/J&J Alliance-Next Generation Stroke Prevention: Factor XI Inhibition in Atrial Fibrillation

Next Generation Stroke Prevention: Factor XI Inhibition in Atrial Fibrillation - Powered by BMS/J&J Alliance

Video Transcription

Video Summary

The panel discussed factor XI inhibition as a new strategy for stroke prevention and atrial fibrillation (AF), focusing on whether these agents can reduce clotting without increasing bleeding. Panelists reviewed the main drug types being tested: oral small molecules, injectable monoclonal antibodies, and antisense agents that reduce factor XI production.  <br /><br />They debated trial results, especially the conflicting OCEANIC studies: one AF trial showed less bleeding but more embolic events, while a stroke trial on top of aspirin showed reduced stroke without more bleeding. The group suggested differences in drug, dose, and trial comparator may explain the mixed outcomes. They agreed that aspirin’s bleeding risk is often underestimated.  <br /><br />A major theme was patient selection. Potential niches include patients with AF plus non-cardioembolic stroke, cancer patients, subclinical AF, and those with high bleeding risk. They also discussed left atrial appendage closure, suggesting these drugs may eventually complement or compete with that strategy.  <br /><br />The panel emphasized practical issues: cost, adherence, reversibility, peri-procedural management, and whether monitoring tests will be needed. They predicted that if approved, factor XI inhibitors will likely be used selectively at first, but may expand as clinicians gain experience and more data emerge.

Keywords

factor XI inhibition

stroke prevention

atrial fibrillation

bleeding risk

OCEANIC trials

oral small molecules

monoclonal antibodies

patient selection